Table of Contents
MAHWAH, N.J. – Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of phytonadione injectable emulsion USP, 10 mg/mL Single Dose Ampules. Glenmark's phytonadione injectable emulsion USP, 10 mg/mL Single Dose Ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., ANDA 087955.
Commenting on the launch, Marc Kikuchi, president & business head, North America at Glenmark said, "We are excited to announce the launch of phytonadione injectable emulsion USP, 10 mg/mL Single Dose Ampules, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients."
According to IQVIA sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million.
